Human Genome (HGSI) Trades Well Above GSK Offer, Other Biotechs See Action
Tweet
Share
E-mailGet Alerts HGSI Hot Sheet
Join SI Premium – FREE
Shares of Human Genome Sciences Inc. (Nasdaq: HGSI) are trading beyond Glaxo's (NYSE: GSK) rejected $13 per share bid on speculation of a higher bid.
Human Genome last traded at $14.50, up 103 percent.
The news is also boosting other biotech stocks on M&A hopes:
Dendreon Corp. (Nasdaq: DNDN) is up 10%
VIVUS Inc. (Nasdaq: VVUS) is indicated higher.
Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) is indicated higher
InterMune Inc. (Nasdaq: ITMN) is indicated higher
Human Genome last traded at $14.50, up 103 percent.
The news is also boosting other biotech stocks on M&A hopes:
Dendreon Corp. (Nasdaq: DNDN) is up 10%
VIVUS Inc. (Nasdaq: VVUS) is indicated higher.
Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) is indicated higher
InterMune Inc. (Nasdaq: ITMN) is indicated higher
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- General Motors (GM) to Move Headquarters to Different Building in Detroit - Reuters
- Tesla (TSLA) to cut over 10% global staff - Electrek
- Informatica (INFA) jumps as Salesforce (CRM) reportedly eyes new mega takeover
Create E-mail Alert Related Categories
Rumors, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
